"I'm wondering if you have found any regular CVD trials with patients without diabetes that may have similar kidney profiles to BETonMACE."

No, I haven't really paid attention to kidney function profiles in other CVOT trials.

"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055448/"

Hmmmm, that's a stretch going from pan-BET inhibitor treatment of a cell line with impaired mitochondrial complex I function grown in artificial conditions to an intact animal model or human treated with complex inter-organ relationships treated with a bromodomain-2 selective BET inhibitor. Thanks for sharing that article, but in my opinion this has little proven relevance to in vivo glucose homeodynamics in a whole animal/human. I would instead argue that the published gene expression, protein and metabolism data from Resverlogix on apabetalone treated primary human hepatocytes would be a much better comparator. And even with that apabetalone primary huyman hepatocyte data.....that should be taken with a grain of salt since glucose homeostatis involves many organs including but not limited to pancreas, liver, brain, muscle, fat, intestine, etc. 

BearDownAZ